

**173rd Vaccines and Related Biological Products Advisory Committee
(VRBPAC) Meeting, June 7, 2022**

VOTING QUESTION

Based on the totality of scientific evidence available, do the benefits of the Novavax COVID-19 Vaccine when administered as a 2-dose series outweigh its risks for use in individuals 18 years of age and older?